The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

被引:124
|
作者
Flechner, SM [1 ]
Zhou, LM [1 ]
Derweesh, I [1 ]
Mastroianni, B [1 ]
Savas, K [1 ]
Goldfarb, D [1 ]
Modlin, CS [1 ]
Krishnamurthi, V [1 ]
Novick, A [1 ]
机构
[1] Cleveland Clin Fdn, Transplant Ctr, Glickman Urol Inst, Sect Renal Transplantat, Cleveland, OH 44195 USA
关键词
D O I
10.1097/01.TP.0000093502.26208.42
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The aim of this study was to determine whether there has been an increase in the incidence or severity of wound-healing complications that can be attributed to the introduction of newer immunosuppressive drugs. Methods. Consecutive series of adult kidney-only transplant recipients were selected from our Unified Transplant Database backward from September 2002. There were 513 patients divided into groups on the basis of their maintenance immunosuppression given for at least the first 30 days posttransplant. Group I (152) was given sirolimus, mycophenolate mofetil, and prednisone (SRL/XMF/P) between March 2000 and September 2002; group II (168) was given cyclosporine A (CsA)/MMF/P between January 1999 and July 2002; and group III (193) was given azathioprine (AzA)/CsA/P between January 1993 and December 1997. A classification system for wound-healing problems was developed, and each of the three groups was analyzed by univariate and multivariate analysis. Results. From groups III to II to 1, there was a significant increase in mean age (42.4 vs. 49 years), percent of patients diabetic (17% vs. 29%), mean body mass index (BMI) (24.2 vs. 27.1 kg/m(2)), and percent BMI greater than 30 (13.5% vs. 27%). The cumulative percentage of all wound-healing problems between group I (19.7%) vs. group II (16.1%) and group III (15.6%) was not significantly different. The most significant risk factor was a recipient BMI greater than 30 (P=0.0012) and delayed graft function (P=0.0041). Conclusions. During a 10-year period marked by changing recipient demographics, the introduction of MMF and SRL did not result in a significant increase in transplant wound-healing complications. The most significant risk factor associated with transplant wound-healing complications remains body weight, which was the major influence for each of the immunosuppressive drug combinations described.
引用
收藏
页码:1729 / 1734
页数:6
相关论文
共 50 条
  • [12] Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion
    Thervet, E
    Morelon, E
    Ducloux, D
    Bererhi, L
    Noël, LH
    Bedrossian, JJ
    Puget, S
    Chalopin, JM
    Mihatsch, M
    Legendre, C
    Kreis, H
    [J]. CLINICAL TRANSPLANTATION, 2000, 14 (06) : 561 - 566
  • [13] Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients
    Kuppahally, S
    Al-Khaldi, A
    Weisshaar, D
    Valantine, HA
    Oyer, P
    Robbins, RC
    Hunt, SA
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (05) : 986 - 992
  • [14] CYCLOSPORINE PHARMACOKINETICS IN KIDNEY-TRANSPLANT RECIPIENTS
    PTACHCINSKI, RJ
    BURCKART, GJ
    VENKATARAMANAN, R
    ROSENTHAL, JT
    TAYLOR, R
    HAKALA, T
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (06): : 501 - 502
  • [15] Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids
    Akman, B.
    Uyar, M.
    Afsar, B.
    Sezer, S.
    Ozdemir, F. N.
    Haberal, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (01) : 135 - 137
  • [16] The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients
    Hulbert, Amanda L.
    Delahunty, April J.
    Rajab, Amer
    Forbes, Rachel C.
    Winters, Holli A.
    [J]. CLINICAL TRANSPLANTATION, 2013, 27 (04) : E521 - E527
  • [17] Pharmacometabolomics identified nonactivated metabolites of azathioprine and mycophenolate mofetil in urine of kidney transplant recipients
    Klont, Frank
    Bakker, Stephan J. L.
    Hak, Eelko
    Touw, Daan J.
    Hopfgartner, Gerard
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1616 - I1616
  • [18] Pharmacokinetic monitoring of mycophenolate mofetil in de novo kidney-transplant patients receiving belatacept or cyclosporine A
    Kamar, Nassim
    Ribes, David
    Lavit, Michel
    Esposito, Laure
    Lavayssiere, Laurence
    Cointault, Olivier
    Salvin, Sylvie
    Durand, Dominique
    Rostaing, Lionel
    [J]. TRANSPLANT INTERNATIONAL, 2007, 20 : 118 - 118
  • [19] Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
    Ahsan, N
    Hricik, D
    Matas, A
    Rose, S
    Tomlanovich, S
    Wilkinson, A
    Ewell, M
    McIntosh, M
    Stablein, D
    Hodge, E
    Hayes, D
    Gores, P
    Cohen, D
    Gonwa, T
    Brinler, K
    Harland, R
    Neylan, J
    Pescovitz, M
    Wynn, J
    Ahsan, N
    Yang, HC
    Bennett, W
    Copley, J
    Wilkinson, A
    Dunn, J
    Tomlanovich, S
    Chan, L
    Bertolatus, JA
    Weir, M
    Mendez, R
    Pirsch, J
    Helderman, JH
    [J]. TRANSPLANTATION, 1999, 68 (12) : 1865 - 1874
  • [20] Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids: Focus on Acute Rejection, Patient and Graft Survival
    Yang, Aifang
    Wang, Bin
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (02) : 98 - 104